Clinical Trial

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

Name: A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease — clinical trial record (NCT07041099)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

A phase 1b, open-label study of CLN-978 administered subcutaneously in patients with active, moderate to severe Sjogren's Disease.

Protocol Amendment History 1 change

notable Trial sites expanded: 11 -> 14 locations 2026-08-12

Trial Details

NCT Number	NCT07041099
Lead Sponsor	Cullinan Therapeutics Inc.
Conditions	Sjögren, Sjogren Disease, Sjogren's Syndrome
Enrollment	36 participants
Start Date	2025-10-01
Primary Completion	2028-03-15 (estimated)
Study Completion	2029-03-15 (estimated)
Updated on ClinicalTrials.gov	2026-08-11